Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 14/20 | 0.64 |
| ▸ | CCR6 | P51684 | 9/20 | 0.55 |
| ▸ | CXCR1 | P25024 | 7/20 | 0.55 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.55 |
| ▸ | CCR4 | P51679 | 3/20 | 0.55 |
| ▸ | CCR7 | P32248 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15434984 | 1.00 | CXCR2 (0.64) | CXCR2CCR6CXCR1CXCR3CCR4 | |
| SCHEMBL2296197 | 1.00 | CXCR2 (0.64) | CXCR2CCR6CXCR1CXCR3CCR4 | |
| SCHEMBL2293322 | 0.86 | CXCR2 (0.63) | CXCR2CCR6CXCR1CXCR3CCR4 | |
| SCHEMBL2293315 | 0.86 | CXCR2 (0.63) | CXCR2CCR6CXCR1CXCR3CCR4 | |
| SCHEMBL9978206 | 0.85 | CXCR2 (0.64) | CXCR2CCR6CXCR1CXCR3CCR4 | |
| SCHEMBL2297787 | 0.83 | CCR6 (0.51) | CXCR2CCR6CXCR1 | |
| SCHEMBL12262979 | 0.83 | CXCR2 (0.75) | CXCR2CCR6CXCR1CXCR3CCR4 | |
| SCHEMBL19678013 | 0.82 | CXCR2 (0.73) | CXCR2CCR6CXCR1CXCR3CCR4 | |
| SCHEMBL20452168 | 0.81 | CXCR2 (0.61) | CXCR2CCR6CXCR1CXCR3CCR4 | |
| SCHEMBL9978025 | 0.81 | CXCR2 (0.61) | CXCR2CCR6CXCR1CXCR3CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115087-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2015-08-25 | — | — | US | disclosed |
| US-20140213594-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-07-31 | — | — | US | disclosed |
| US-8722925-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2014-05-13 | — | — | US | disclosed |
| EP-2310359-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-01-15 | — | — | EP | disclosed |
| US-20130005735-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2013-01-03 | — | — | US | disclosed |
| US-8329754-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2012-12-11 | — | — | US | disclosed |
| US-8288588-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20110251205-A1 | SQUARAMIDE DERIVATIVES AS CXCR2 ANTAGONIST | NOVARTIS AG | 2011-10-13 | — | — | US | disclosed |
| US-20110251206-A1 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG | 2011-10-13 | — | — | US | disclosed |
| US-7989497-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-20100029670-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251206-A1 | Squaramide derivatives as CXCR2 antagonist | CXCR2, CXCR3, CXCR1 | CXCR2 1/4885CCR6 57/4885CXCR1 3/4885 |
| US-20110251205-A1 | SQUARAMIDE DERIVATIVES AS CXCR2 ANTAGONIST | CXCR2, CXCR3, CXCR1 | CXCR2 1/4885CCR6 57/4885CXCR1 3/4885 |
| US-20100029670-A1 | ORGANIC COMPOUNDS | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885CCR6 30/4885CXCR1 2/4885 |
| US-20130005735-A1 | ORGANIC COMPOUNDS | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885CCR6 30/4885CXCR1 2/4885 |
| US-20140213594-A1 | ORGANIC COMPOUNDS | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885CCR6 30/4885CXCR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.